Treatment Satisfaction with Calcitonin Gene-Linked Peptide Monoclonal Antibodies as a New Measure of Patient-Reported Outcomes: A Real Experience in Migraine

This article was originally published here

Acta Neurol Scan. 2022 Mar 3. doi: 10.1111/ane.13599. Online ahead of print.


BACKGROUND: To assess treatment satisfaction with galcanezumab as a patient-reported outcome measure (PROM) in migraine.

METHODS: Patients with ≥8 headache days/month who had failed ≥3 medications were included. Demographic and medical histories were collected. Patient satisfaction (effectiveness, safety, convenience and overall satisfaction [GS]) was assessed by the Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM-1.4©).

RESULTS: We included 30 patients with migraine (76.7% chronic migraine). After 12 weeks of treatment with galcanezumab, the median monthly headache days (MHD) decreased by 11.5 (IQR 14.0) and the median monthly migraine days (MMD) decreased by 9.0 (IQR 7, 5); at 24 weeks the change was 15.0 (IQR 12.0) and 8.0 days (IQR 6.0). The HIT-6 score improved from 68.0 (IQR 7.5) to 54.0 (IQR 9.5) at 12 weeks (p

CONCLUSIONS: The results of this study suggest that migraine patients receiving galcanezumab are significantly more satisfied compared to other preventive treatments, associating GS treatment with significant reductions in frequency, impact, and disability. by migraine.

PMID:35243611 | DOI:10.1111/ane.13599

About Antoine L. Cassell

Check Also

IMU-838 treatment associated with low rate of confirmed disability worsening in relapsing MS

Recently reported interim data from the Phase 2 EMPhASIS trial (NCT03846219) of Immunic’s investigational agent, …

Leave a Reply

Your email address will not be published.